샘플 요청 목록

 카트 문의
시장보고서
상품코드
2158533

인간용 백신 시장

Human Vaccines
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 448 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,913,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,036,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,741,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 인간용 백신 시장은 2032년까지 987억 달러에 달할 것으로 전망됩니다.

2025년 706억 달러로 추산되는 세계 인간용 백신 시장은 2025-2032년의 분석 기간 동안 연평균 성장률(CAGR) 4.9%를 기록하며, 2032년까지 987억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석 대상으로 다루고 있는 부문 중 하나인 ‘바이러스성 백신’은 연평균 성장률(CAGR) 5.1%를 기록하며, 분석 기간이 끝날 때까지 295억 달러에 달할 것으로 예측됩니다. ‘세균성 백신’ 부문의 성장률은 분석 기간 동안 연평균 성장률(CAGR) 5.8%를 나타낼 것으로 추정됩니다.

미국 시장은 192억 달러로 추산되는 반면, 중국은 연평균 성장률(CAGR) 8.5%를 나타낼 것으로 예측됩니다.

2025년 미국의 인간용 백신 시장 규모는 192억 달러로 추산됩니다. 세계 2위의 경제 규모를 자랑하는 중국의 경우, 2025-2032년의 분석 기간 동안 연평균 성장률(CAGR) 8.5%를 기록하며, 2032년까지 시장 규모가 209억 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 2.3% 및 3.9%를 나타낼 것으로 예측됩니다. 유럽 내에서는 독일이 연평균 성장률(CAGR) 약 3.1%를 나타낼 것으로 예측됩니다.

세계 인간용 백신 시장 - 주요 동향 및 촉진요인 개요

인체용 백신의 힘: 현대 의학의 초석

인간용 백신은 공중보건 분야에서 가장 큰 성과 중 하나로, 면역 체계가 병원체를 인식하고 이에 대항하도록 훈련시킴으로써 수많은 감염병에 대한 방어 기능을 제공합니다. 병원체를 모방한 항원으로 구성된 백신은 면역 체계가 신속하고 효과적으로 질병과 싸울 수 있도록 준비하는 데 매우 중요합니다. 이러한 메커니즘 덕분에 천연두와 소아마비 등 수많은 생명을 위협하는 질병의 근절 및 감소가 성공적으로 이루어졌으며, 세계적으로 발병률과 사망률이 대폭 감소했습니다. 백신은 개인을 보호할 뿐만 아니라 집단 면역 형성에 기여하여 지역 사회 내 감염병의 확산을 막고, 나아가 세계 공중보건의 확보로 이어지고 있습니다.

새로운 개척지를 향한 과제: 백신의 유효성과 안전성을 높이는 혁신

백신 기술 분야는 끊임없이 진화하고 있으며, 더 높은 보호 효과와 안전성을 약속하는 새로운 기법이 도입되고 있습니다. 기존의 백신 전략도 효과적이지만, 현재는 mRNA 백신이나 재조합 기술과 같은 최첨단 접근법을 통해 더욱 강화되고 있습니다. 이러한 혁신 기술은 정밀한 표적화와 신속한 규모 확대를 가능하게 하며, 특히 코로나19 팬데믹과 같은 세계적 과제에 신속하게 대응하는 데 중요한 역할을 하고 있습니다. 또한, 보조제 및 개선된 투여 시스템의 개발은 백신의 효능에 계속해서 혁명을 일으키고 있으며, 더 복잡한 질병과의 싸움 가능성을 넓히고, 다양한 집단에 맞춘 예방 접종을 실현하고 있습니다.

세계 백신 산업을 재편하는 새로운 동향

세계의 인구 동향과 기술 동향이 백신 산업의 양상을 새롭게 바꾸고 있습니다. 국제적인 이동 증가와 도시화의 진전은 감염병 전파 위험을 높이며, 효과적인 백신 접종 프로그램의 필요성을 더욱 강조하고 있습니다. 동시에 건강에 대한 인식 제고와 의료 인프라 개선으로 인해 세계적으로, 특히 그동안 충분한 의료 서비스를 받지 못했던 지역에서 백신 접종률이 상승하고 있습니다. 디지털을 활용한 예방접종 추적 및 헬스케어 분야의 AI와 같은 기술 발전 또한 백신 접종 캠페인의 도달 범위와 효율성을 높여, 보다 광범위하고 효과적인 접종을 가능하게 하고 있습니다.

인체용 백신 시장의 성장을 견인하는 요인은 무엇일까？

인간용 백신 시장의 성장은 감염병 확산, 세계적인 건강 의식 고취, 백신 연구 개발의 진전 등 여러 요인에 의해 주도되고 있습니다. 감염병을 근절하기 위한 정부 및 국제 보건 기구의 자금 지원과 투자 확대는 백신 분야의 확장과 혁신에 크게 기여하고 있습니다. 특히, 코로나19 팬데믹은 세계 보건 안보에서 백신이 차지하는 지극히 중요한 역할을 부각시켰으며, 백신 개발과 배포에 초점을 맞춘 전례 없는 민관 협력을 이끌어 냈습니다. 또한, 고령화와 감염병에 대한 취약성을 높이는 만성 질환 증가와 같은 인구통계학적 요인으로 인해 지속적인 백신 개발과 접종이 필수적입니다. 이러한 동향들은 종합적으로 현대 의학 및 공중보건에서 백신이 수행하는 지극히 중요한 역할을 강조하며, 이 필수적인 분야에 대한 지속적인 투자와 연구 개발을 보장하고 있습니다.

부문:

적응증(바이러스 백신, 세균 백신, 암 백신, 알레르기 백신, 기타 적응증), 투여 경로(경구 투여, 비경구 투여, 비강 투여), 연령대(소아, 성인), 유통 채널(병원·소매 약국, 정부 조달 기관, 기타 유통 채널)

주요 기업

  • ALK-Abello A/S
  • Altimmune, Inc.
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech
  • BiondVax Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Janssen Pharmaceuticals Inc.
  • MedImmune
  • Mitsubishi Tanabe Pharma
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • SK BioScience
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila

해당 분야의 전문가 관점을 바탕으로 합니다. 산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 - 기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다-컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업 공시 정보, 연차 보고서, 기관지 및 기타 검증된 정보원에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.11.04

Global Human Vaccines Market to Reach US$98.7 Billion by 2032

The global market for Human Vaccines estimated at US$70.6 Billion in the year 2025, is expected to reach US$98.7 Billion by 2032, growing at a CAGR of 4.9% over the analysis period 2025-2032. Viral Vaccines Indication, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$29.5 Billion by the end of the analysis period. Growth in the Bacterial Vaccines Indication segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.2 Billion While China is Forecast to Grow at 8.5% CAGR

The Human Vaccines market in the U.S. is estimated at US$19.2 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$20.9 Billion by the year 2032 trailing a CAGR of 8.5% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Human Vaccines Market - Key Trends and Drivers Summarized

Unveiling the Power of Human Vaccines: A Cornerstone of Modern Medicine

Human vaccines stand as one of the greatest achievements in public health, offering protection against a myriad of infectious diseases by training the immune system to recognize and combat pathogens. Comprising antigens that mimic disease-causing organisms, vaccines are crucial in preparing the immune system to fight diseases quickly and effectively. This mechanism has successfully led to the eradication and reduction of numerous life-threatening diseases, such as smallpox and polio, significantly lowering morbidity and mortality worldwide. Vaccines not only safeguard individuals but also contribute to herd immunity, preventing the spread of infections across communities and thereby securing population health globally.

Navigating New Frontiers: Innovations Enhancing Vaccine Efficacy and Safety

The landscape of vaccine technology is constantly evolving, incorporating novel methods that promise greater protection and safety. Traditional vaccine strategies, while effective, are now being enhanced with cutting-edge approaches like mRNA vaccines and recombinant technologies. These innovations offer precise targeting and rapid scalability, particularly highlighted by their role in addressing global challenges such as the COVID-19 pandemic swiftly. Furthermore, the development of adjuvants and improved delivery systems continues to revolutionize vaccine efficacy, broadening the horizons for combating more complex diseases and tailoring immunizations to diverse populations.

Emerging Trends Reshaping the Global Vaccine Sector

Global demographic and technological trends are reshaping the vaccine industry. The increase in international travel and urbanization elevates the risk of infectious disease transmission, amplifying the need for effective vaccination programs. Simultaneously, rising health consciousness and improved healthcare infrastructure are driving up vaccine uptake globally, especially in regions previously underserved. Technological advancements such as digital immunization tracking and AI in healthcare are also enhancing the reach and efficiency of vaccination campaigns, ensuring wider and more effective coverage.

What Drives the Growth in the Human Vaccines Market?

The growth in the human vaccines market is driven by several factors, including the increasing prevalence of infectious diseases, rising global health awareness, and advancements in vaccine research and development. Enhanced funding and investments by governments and global health organizations to eliminate infectious diseases contribute significantly to the expansion and innovation within the vaccine sector. The COVID-19 pandemic has particularly highlighted the critical role of vaccines in global health security, leading to unprecedented public and private partnerships focused on vaccine development and distribution. Moreover, demographic factors such as aging populations and the rise in chronic health conditions that increase susceptibility to infections necessitate continued vaccine development and uptake. Together, these dynamics underscore the vital role of vaccines in contemporary medicine and public health, ensuring ongoing investment and research in this essential field.

SCOPE OF STUDY:

The report analyzes the Human Vaccines market by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication, Other Indications); Administration Route (Oral Administration Route, Parenteral Administration Route, Nasal Administration Route); Age Group (Pediatric Age Group, Adult Age Group); Distribution Channel (Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • ALK - Abello A/S
  • Altimmune, Inc.
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • Bharat Biotech
  • BiondVax Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Janssen Pharmaceuticals Inc.
  • MedImmune
  • Mitsubishi Tanabe Pharma
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • SK BioScience
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Human Vaccines - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 16 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Genetic and Recombinant Technology Expands Vaccine Efficacy
    • Demand Grows for Pediatric and Adult Vaccines Globally
    • Rising Awareness and Education About Vaccine Preventable Diseases
    • Integration of AI and Machine Learning in Vaccine Development
    • Innovations in Vaccine Delivery Systems and Adjuvants
    • Vaccination Programs on Public Health Systems Spur Vaccines Usage & Penetration Among Susceptible Populations
    • Emergence of New Pathogens Drives Demand for Novel Vaccines
    • Vaccine to Prevent HIV Still in the Pipeline
    • R&D Interest in Personalized Cancer Vaccines Gains Momentum
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Vaccines Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Human Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Viral Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Viral Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Viral Vaccines Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Bacterial Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Bacterial Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Bacterial Vaccines Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Cancer Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Cancer Vaccines Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Allergy Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Allergy Vaccines Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Allergy Vaccines Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Parenteral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Parenteral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Parenteral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Nasal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Nasal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Nasal Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital & Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Hospital & Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Hospital & Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Government Suppliers Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Government Suppliers Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Government Suppliers Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 42: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: World 13-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: USA Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: USA 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 47: USA Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: USA Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 50: USA Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: USA Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: USA 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 53: USA Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 54: USA Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: USA 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Canada Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Canada 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Canada Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Canada 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Canada Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: Canada 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Canada Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: Canada 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • JAPAN
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Japan Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Japan 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Japan Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Japan 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Japan Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Japan 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Japan Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Japan 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • CHINA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: China Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: China 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 83: China Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: China Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: China 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 86: China Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: China Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: China 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 89: China Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: China Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: China 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • EUROPE
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Europe Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Europe 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 96: Europe Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Europe 13-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Europe Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Europe 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Europe Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Europe 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Europe Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Europe 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • FRANCE
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: France Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: France 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 110: France Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: France Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: France 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 113: France Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: France Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: France 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 116: France Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: France Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: France 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • GERMANY
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Germany Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: Germany 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Germany Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: Germany 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Germany Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: Germany 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Germany Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: Germany 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Italy Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Italy 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Italy Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Italy 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Italy Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Italy 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Italy Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Italy 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: UK Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: UK 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 146: UK Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: UK Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: UK 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 149: UK Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: UK Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: UK 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 152: UK Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: UK Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: UK 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Spain Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Spain 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Spain Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Spain 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Spain Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Spain 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Spain Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Spain 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Russia Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Russia 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Russia Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Russia 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Russia Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Russia 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Russia Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Russia 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Rest of Europe 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Rest of Europe 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Rest of Europe 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Rest of Europe 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Human Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Asia-Pacific 13-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Asia-Pacific 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: Asia-Pacific 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: Asia-Pacific 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Asia-Pacific 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Australia Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Australia 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Australia Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Australia 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Australia Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Australia 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Australia Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 217: Australia 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • INDIA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 219: India Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 220: India 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 221: India Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 222: India Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 223: India 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 224: India Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 225: India Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 226: India 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 227: India Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 228: India Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 229: India 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 231: South Korea Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 232: South Korea 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 234: South Korea Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 235: South Korea 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 237: South Korea Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 238: South Korea 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 240: South Korea Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 241: South Korea 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Latin America Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 256: Latin America 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 258: Latin America Historic Review for Human Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 259: Latin America 13-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Latin America Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 262: Latin America 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Latin America Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 265: Latin America 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Latin America Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 268: Latin America 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Argentina Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 271: Argentina 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Argentina Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 274: Argentina 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Argentina Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 277: Argentina 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Argentina Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 280: Argentina 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Brazil Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 283: Brazil 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Brazil Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 286: Brazil 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 288: Brazil Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 289: Brazil 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 291: Brazil Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 292: Brazil 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 294: Mexico Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 295: Mexico 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Mexico Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 298: Mexico 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Mexico Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 301: Mexico 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Mexico Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 304: Mexico 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 307: Rest of Latin America 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 310: Rest of Latin America 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 313: Rest of Latin America 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 316: Rest of Latin America 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 318: Middle East Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 319: Middle East 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 321: Middle East Historic Review for Human Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 322: Middle East 13-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 324: Middle East Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 325: Middle East 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 327: Middle East Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 328: Middle East 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 330: Middle East Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 331: Middle East 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 333: Iran Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 334: Iran 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 336: Iran Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 337: Iran 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 339: Iran Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 340: Iran 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 342: Iran Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 343: Iran 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 345: Israel Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 346: Israel 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 348: Israel Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 349: Israel 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 351: Israel Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 352: Israel 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 354: Israel Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 355: Israel 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 358: Saudi Arabia 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 361: Saudi Arabia 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 364: Saudi Arabia 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 367: Saudi Arabia 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 369: UAE Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 370: UAE 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 372: UAE Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 373: UAE 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 375: UAE Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 376: UAE 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 378: UAE Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 379: UAE 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 382: Rest of Middle East 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 385: Rest of Middle East 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 388: Rest of Middle East 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 391: Rest of Middle East 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032
  • AFRICA
    • Human Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 393: Africa Historic Review for Human Vaccines by Administration Route - Oral Administration Route, Parenteral Administration Route and Nasal Administration Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 394: Africa 13-Year Perspective for Human Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Parenteral Administration Route and Nasal Administration Route for the Years 2020, 2026 & 2032
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 396: Africa Historic Review for Human Vaccines by Indication - Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 397: Africa 13-Year Perspective for Human Vaccines by Indication - Percentage Breakdown of Value Sales for Viral Vaccines Indication, Bacterial Vaccines Indication, Cancer Vaccines Indication, Allergy Vaccines Indication and Other Indications for the Years 2020, 2026 & 2032
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 399: Africa Historic Review for Human Vaccines by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 400: Africa 13-Year Perspective for Human Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2020, 2026 & 2032
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 402: Africa Historic Review for Human Vaccines by Distribution Channel - Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 403: Africa 13-Year Perspective for Human Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies Distribution Channel, Government Suppliers Distribution Channel and Other Distribution Channels for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기